Abstract
Background Covid-19, the disease caused by SARS-CoV-2, is associated with significant respiratory-related morbidity and mortality. Angiotensin receptor blockers (ARBs) have been postulated as tentative pharmacological agents to treat Covid-19-induced lung inflammation.
Trial design This trial is a parallel group, randomized, two arm, open label, multicenter superiority trial with 1:1 allocation ratio.
Methods Participants included patients who were 18 years of age or older and who had been hospitalized with confirmed Covid-19 with 4 or fewer days since symptom onset. Exclusion criteria included intensive care unit admission prior to randomization and use of angiotensin receptor blocker or angiotensin converting enzyme inhibitors at admission. Participants in the treatment arm received telmisartan 80 mg bid during 14 days plus standard care. Participants in the control arm received standard care alone.
Primary outcome was to achieve significant reductions in plasma levels of C-reactive protein in telmisartan treated Covid-19 patients at day 5 and 8 after randomization. Key secondary outcomes included time to discharge evaluated at 15 days after randomization and admission to ICU and death at 15-and 30-days post randomization. We present here a preliminary report.
Results A total of 78 patients were included in the interim analysis, 40 in the telmisartan and 38 in the control groups. CRP levels at day 5 in the control group were 51.1 ± 44.8 mg/L (mean ± SD; n=28) and in the telmisartan group were 24.2 ± 31.4 mg/L (mean ± SD; n=32, p<0.05). At day 8, CRP levels were 41.6 ± 47.6 mg/L (mean ± SD; n=16) and 9.0 ± 10.0 mg/L (mean ± SD; n=13, p < 0.05) in the control and telmisartan groups, respectively. Also, analysis of time to discharge by Kaplan-Meier method showed that telmisartan treated patients had statistically significant lower time to discharge (median time to discharge control group=15 days; telmisartan group=9 days). No differences were observed for ICU admission or death. No significant adverse events related to telmisartan were reported.
Conclusions In the present preliminary report, despite the small number of patients studied, ARB telmisartan, a well-known inexpensive safe antihypertensive drug, administered in high doses, demonstrates anti-inflammatory effects and improved morbidity in hospitalized patients infected with SARS -CoV-2, providing support for its use in this serious pandemia (NCT04355936).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04355936
Funding Statement
The School of Medicine, University of Buenos Aires, provided material support through permission to use Hospital de Clinicas facilities to carry out the trial. Also, all biochemical determinations at Hospital de Clinicas were carried out at its Central Laboratory Facility. Hospital Espanol de Buenos Aires provided material support through permission to use its facilities to carry out the trial. Also, all biochemical determinations at this site were carried out at the Central Laboratory Facility at Hospital Espanol. Laboratorios Elea Phoenix provided the telmisartan tablets used for the study and provided assistance in submitting the registration of this trial to www.ClinicalTrials.com. The sponsors had no role in the design of this study neither had any role during its execution, analyses, interpretation of the data, or decision to submit results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol and its modifications were approved by the ethics committee of Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires and by the Institutional Review Board at Hospital Espanol de Buenos Aires.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data of individual participants that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be made available upon publication for 5 years at a third-party website (DOI: 10.5281/zenodo.3970223)
